Article

MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels

Received:
Accepted:
Published online:

Abstract

The hepatic low-density lipoprotein receptor (LDLR) pathway is essential for clearing circulating LDL cholesterol (LDL-C). Whereas the transcriptional regulation of LDLR is well characterized, the post-transcriptional mechanisms that govern LDLR expression are just beginning to emerge. Here we develop a high-throughput genome-wide screening assay to systematically identify microRNAs (miRNAs) that regulate LDLR activity in human hepatic cells. From this screen we identified and characterized miR-148a as a negative regulator of LDLR expression and activity and defined a sterol regulatory element–binding protein 1 (SREBP1)-mediated pathway through which miR-148a regulates LDL-C uptake. In mice, inhibition of miR-148a increased hepatic LDLR expression and decreased plasma LDL-C. Moreover, we found that miR-148a regulates hepatic expression of ATP-binding cassette, subfamily A, member 1 (ABCA1) and circulating high-density lipoprotein cholesterol (HDL-C) levels in vivo. These studies uncover a role for miR-148a as a key regulator of hepatic LDL-C clearance through direct modulation of LDLR expression and demonstrate the therapeutic potential of inhibiting miR-148a to ameliorate an elevated LDL-C/HDL-C ratio, a prominent risk factor for cardiovascular disease.

  • Subscribe to Nature Medicine for full access:

    $225

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    & Atherosclerosis. the road ahead. Cell 104, 503–516 (2001).

  2. 2.

    Atherosclerosis. Nature 407, 233–241 (2000).

  3. 3.

    & The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331–340 (1997).

  4. 4.

    , , & LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 325, 100–104 (2009).

  5. 5.

    et al. SREBP-2, a second basic-helix-loop-helix–leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc. Natl. Acad. Sci. USA 90, 11603–11607 (1993).

  6. 6.

    , , & ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol. Cell. Biol. 13, 4753–4759 (1993).

  7. 7.

    et al. SREBP-1, a basic-helix-loop-helix–leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 75, 187–197 (1993).

  8. 8.

    & Regulation of the mevalonate pathway. Nature 343, 425–430 (1990).

  9. 9.

    et al. A conserved SREBP-1–phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. Cell 147, 840–852 (2011).

  10. 10.

    et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA 100, 12027–12032 (2003).

  11. 11.

    , , , & Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J. Lipid Res. 44, 2109–2119 (2003).

  12. 12.

    & Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu. Rev. Med. 57, 313–329 (2006).

  13. 13.

    The functions of animal microRNAs. Nature 431, 350–355 (2004).

  14. 14.

    MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233 (2009).

  15. 15.

    , & Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 9, 102–114 (2008).

  16. 16.

    et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 328, 1570–1573 (2010).

  17. 17.

    et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328, 1566–1569 (2010).

  18. 18.

    et al. An SREBP-responsive microRNA operon contributes to a regulatory loop for intracellular lipid homeostasis. Cell Metab. 18, 51–61 (2013).

  19. 19.

    et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J. Clin. Invest. 121, 2921–2931 (2011).

  20. 20.

    et al. Inhibition of miR-33a/b in nonhuman primates raises plasma HDL and lowers VLDL triglycerides. Nature 478, 404–407 (2011).

  21. 21.

    et al. Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR. Sci. Transl. Med. 5, 212ra162 (2013).

  22. 22.

    et al. MicroRNA-144 regulates hepatic ABCA1 and plasma HDL following activation of the nuclear receptor FXR. Circ. Res. 112, 1602–1612 (2013).

  23. 23.

    et al. Control of cholesterol metabolism and plasma HDL levels by miRNA-144. Circ. Res. 112, 1592–1601 (2013).

  24. 24.

    et al. MicroRNA-223 coordinates cholesterol homeostasis. Proc. Natl. Acad. Sci. USA 111, 14518–14523 (2014).

  25. 25.

    et al. LNA-mediated microRNA silencing in nonhuman primates. Nature 452, 896–899 (2008).

  26. 26.

    et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to upregulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 36, 1153–1162 (2008).

  27. 27.

    et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3, 87–98 (2006).

  28. 28.

    , , , & MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat. Med. 19, 892–900 (2013).

  29. 29.

    , & Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts by lipoproteins. Proc. Natl. Acad. Sci. USA 70, 2162–2166 (1973).

  30. 30.

    , , & Release of low-density lipoprotein from its cell surface receptor by sulfated glycosaminoglycans. Cell 7, 85–95 (1976).

  31. 31.

    , & A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J. Biomol. Screen. 4, 67–73 (1999).

  32. 32.

    et al. Statistical methods for analysis of high-throughput RNA interference screens. Nat. Methods 6, 569–575 (2009).

  33. 33.

    et al. MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues. Genome Res. 14, 2486–2494 (2004).

  34. 34.

    et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129, 1401–1414 (2007).

  35. 35.

    et al. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology 57, 533–542 (2013).

  36. 36.

    & Individual mRNA expression profiles reveal the effects of specific microRNAs. Genome Biol. 9, R82 (2008).

  37. 37.

    et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat. Genet. 45, 1345–1352 (2013).

  38. 38.

    Global Lipids Genetics Consortium. et al. Discovery and refinement of loci associated with lipid levels. Nat. Genet. 45, 1274–1283 (2013).

  39. 39.

    et al. Genome-wide identification of microRNA expression quantitative trait loci. Nat. Commun. 6, 6601 (2015).

  40. 40.

    et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474, 649–653 (2011).

  41. 41.

    et al. RNAi screening reveals proteasome- and Cullin3-dependent stages in vaccinia virus infection. Cell Rep. 2, 1036–1047 (2012).

  42. 42.

    et al. Human MicroRNA targets. PLoS Biol. 2, e363 (2004).

  43. 43.

    , & Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15–20 (2005).

  44. 44.

    , & miRWalk database for miRNA-target interactions. Methods Mol. Biol. 1182, 289–305 (2014).

  45. 45.

    , & Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57 (2009).

  46. 46.

    et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 39, D561–D568 (2011).

  47. 47.

    et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 13, 2129–2141 (2003).

  48. 48.

    & Computational detection and location of transcription start sites in mammalian genomic DNA. Genome Res. 12, 458–461 (2002).

  49. 49.

    , & Genomic analysis of human microRNA transcripts. Proc. Natl. Acad. Sci. USA 104, 17719–17724 (2007).

  50. 50.

    & Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat. Biotechnol. 28, 817–825 (2010).

  51. 51.

    et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473, 43–49 (2011).

  52. 52.

    et al. The human genome browser at UCSC. Genome Res. 12, 996–1006 (2002).

  53. 53.

    , & Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem. 274, 30028–30032 (1999).

  54. 54.

    , , , & Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J. Clin. Invest. 99, 838–845 (1997).

  55. 55.

    , , & Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc. Natl. Acad. Sci. USA 95, 5987–5992 (1998).

  56. 56.

    et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93, 693–704 (1998).

  57. 57.

    et al. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol. Cell. Biol. 21, 2991–3000 (2001).

  58. 58.

    , & Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. 34, 1637–1659 (1993).

  59. 59.

    & ABCA1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins. Curr. Opin. Lipidol. 11, 253–260 (2000).

  60. 60.

    et al. Identification of miR-185 as a regulator of de novo cholesterol biosynthesis and low density lipoprotein uptake. J. Lipid Res. 55, 226–238 (2014).

  61. 61.

    et al. MicroRNA 33 regulates glucose metabolism. Mol. Cell. Biol. 33, 2891–2902 (2013).

  62. 62.

    et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc. Natl. Acad. Sci. USA 108, 9232–9237 (2011).

  63. 63.

    , , & Dicer-dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ. Res. 100, 1164–1173 (2007).

  64. 64.

    et al. A regulatory role for microRNA 33* in controlling lipid metabolism gene expression. Mol. Cell. Biol. 33, 2339–2352 (2013).

  65. 65.

    , , & Control of very low–density lipoprotein secretion by N-ethylmaleimide–sensitive factor and miR-33. Circ. Res. 115, 10–22 (2014).

  66. 66.

    , , , & Human CD36 is a high-affinity receptor for the native lipoproteins HDL, LDL and VLDL. J. Lipid Res. 39, 777–788 (1998).

  67. 67.

    et al. Synergistic upregulation of low-density lipoprotein receptor activity by tamoxifen and lovastatin. Cardiovasc. Res. 64, 346–355 (2004).

  68. 68.

    , , , & Autoregulation of glypican-1 by intronic microRNA-149 fine tunes the angiogenic response to FGF2 in human endothelial cells. J. Cell Sci. 127, 1169–1178 (2014).

  69. 69.

    et al. MicroRNA-758 regulates cholesterol efflux through post-transcriptional repression of ATP-binding cassette transporter A1. Arterioscler. Thromb. Vasc. Biol. 31, 2707–2714 (2011).

  70. 70.

    et al. Radixin is required to maintain apical canalicular membrane structure and function in rat hepatocytes. Gastroenterology 131, 878–884 (2006).

  71. 71.

    et al. Resveratrol prevents high fat/sucrose diet-induced central arterial wall inflammation and stiffening in nonhuman primates. Cell Metab. 20, 183–190 (2014).

  72. 72.

    et al. Long-term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice. EMBO Mol. Med. 6, 1133–1141 (2014).

  73. 73.

    et al. MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS ONE 8, e72324 (2013).

Download references

Acknowledgements

We thank C. Yun, J. Recio, S. Katz and R. DasGupta at the New York University (NYU) RNAi Core for their advice and assistance with the miRNA screen, K. Harry and members of the Yale University Liver Center for primary mouse hepatocyte isolation, members of the Iwakiri laboratory for reagents and advice on primary hepatocyte culture, the Yale University School of Medicine Mouse Metabolic Phenotyping Center (MMPC) for liver toxicity measurements, P. Tontonoz (UCLA) for generously providing the LDLR-GFP plasmid, the Nonhuman Primate Core of the National Institute on Aging for providing liver samples and E. Fisher (NYU School of Medicine) for kindly providing the human hepatocellular carcinoma cell line (Huh7) and mouse hepatic cell line (Hepa1–6). This work was supported through grants by the US National Institutes of Health (NIH; grants R01HL107953, R01HL107953-04S1 and R01HL106063 (C.F.-H.); grant R01HL105945 (Y.S.); grant 1F31AG043318 (L.G.); grant P30KD034989 (Yale University Liver Center), the American Heart Association (grant 15SDG23000025 (C.M.R.)), the Howard Hughes Medical Institute International Student Research Fellowship (E.A.), the Foundation Leducq Transatlantic Network of Excellence in Cardiovascular Research (C.F.-H.) and the Ministerio de Industria y Comercio, Spain (grant SAF2011-29951 (M.A.L.)). Centro de Investigación Biomédica en Red Fisiopatología de Obesidad y Nutrición (CIBERobn) is an initiative of Instituto de Salud Carlos III (ISCIII), Spain. R.d.C. is supported by the Intramural Research Program of the NIH, National Institute of Aging. A.M.N. and A.W. are supported by NIH grant R01DK 094184. The NYU RNAi core is supported by the Laura and Isaac Perlmutter Cancer Center (NIH, National Cancer Institute grant P30CA16087) and the New York State Stem Cell Science (NYSTEM) contract C026719. The Yale University School of Medicine MMPC is supported by NIH grant U24 DK059635.

Author information

Author notes

    • Noemi Rotllan
    •  & Alberto Canfrán-Duque

    These authors contributed equally to this work.

Affiliations

  1. Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, Connecticut, USA.

    • Leigh Goedeke
    • , Noemi Rotllan
    • , Alberto Canfrán-Duque
    • , Juan F Aranda
    • , Cristina M Ramírez
    • , Elisa Araldi
    • , Yajaira Suárez
    •  & Carlos Fernández-Hernando
  2. Integrative Cell Signaling and Neurobiology of Metabolism Program, Section of Comparative Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.

    • Leigh Goedeke
    • , Noemi Rotllan
    • , Alberto Canfrán-Duque
    • , Juan F Aranda
    • , Cristina M Ramírez
    • , Elisa Araldi
    • , Yajaira Suárez
    •  & Carlos Fernández-Hernando
  3. Department of Medicine, Leon H. Charney Division of Cardiology, New York University School of Medicine, New York, New York, USA.

    • Leigh Goedeke
    • , Juan F Aranda
    • , Elisa Araldi
    • , Chin-Sheng Lin
    • , Yajaira Suárez
    •  & Carlos Fernández-Hernando
  4. Department of Cell Biology, New York University School of Medicine, New York, New York, USA.

    • Leigh Goedeke
    • , Elisa Araldi
    • , Chin-Sheng Lin
    • , Yajaira Suárez
    •  & Carlos Fernández-Hernando
  5. Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

    • Norma N Anderson
    •  & Jay D Horton
  6. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

    • Norma N Anderson
    •  & Jay D Horton
  7. Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts, USA.

    • Alexandre Wagschal
    •  & Anders M Näär
  8. Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA.

    • Alexandre Wagschal
    •  & Anders M Näär
  9. Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA.

    • Rafael de Cabo
  10. Servicio de Bioquímica-Investigación, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.

    • Miguel A Lasunción
  11. Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición, Madrid, Spain.

    • Miguel A Lasunción

Authors

  1. Search for Leigh Goedeke in:

  2. Search for Noemi Rotllan in:

  3. Search for Alberto Canfrán-Duque in:

  4. Search for Juan F Aranda in:

  5. Search for Cristina M Ramírez in:

  6. Search for Elisa Araldi in:

  7. Search for Chin-Sheng Lin in:

  8. Search for Norma N Anderson in:

  9. Search for Alexandre Wagschal in:

  10. Search for Rafael de Cabo in:

  11. Search for Jay D Horton in:

  12. Search for Miguel A Lasunción in:

  13. Search for Anders M Näär in:

  14. Search for Yajaira Suárez in:

  15. Search for Carlos Fernández-Hernando in:

Contributions

L.G. and C.F.-H. conceived and designed the study. L.G. optimized and performed the miRNA screen. J.F.A. and A.C.-D. performed confocal experiments, assisted with cloning and analyzed data. L.G. and A.C.-D. performed in vitro experiments and analyzed data. L.G., N.R., C.M.R. and A.C.-D. performed mouse experiments and analyzed data. N.R. performed western blotting for plasma lipoproteins and assessed lipoprotein distribution by FPLC. E.A. cloned the MIR148A promoter. C.-S.L. assisted with western blotting. N.N.A. analyzed gene expression in the livers of fed and fasted wild-type mice and ob/ob mice. R.d.C. designed the nonhuman primate experiments and J.D.H. provided the mouse samples. M.A.L. provided DiI-LDL and native LDL. A.W. and A.M.N. assisted with mouse experiments. Y.S. and C.F.-H. assisted with experimental design and data interpretation. L.G. and C.F.-H. wrote the manuscript, which was commented on by all authors.

Competing interests

C.F.-H. and L.G. have filed a patent (United States PCT/US2014/042196) for the therapeutic use of miR-148 inhibitors in treating cardiometabolic diseases.

Corresponding author

Correspondence to Carlos Fernández-Hernando.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–10 and Supplementary Table 2

Excel files

  1. 1.

    Supplementary Table 1

    Raw data from primary miRNA screen.

  2. 2.

    Supplementary Table 3

    Functional annotation clusters of human miR-148a targets identified by DAVID.